ABIVAX First-Half 2019 Financial Results and Operations Update - Business Wire

ABIVAX First-Half 2019 Financial Results and Operations Update  Business Wire

Nine-month Phase 2a maintenance study confirmed further clinical improvements, with durability of efficacy and safety of ABX464 in ulcerative colitis patients.